

Vemlidy® Registration In The Developing World

Approved

1. Argentina	December 2017	11. Mexico	December 2017
2. Chile	March 2019	12. Mongolia	June 2017
3. Costa Rica	December 2018	13. Mozambique	December 2018
4. Dominican Republic	October 2018	14. Nigeria	January 2019
5. El Salvador	May 2018	15. Panama	September 2018
6. Guatemala	June 2018	16. Philippines	March 2019
7. India	October 2017	17. Thailand	August 2018
8. Indonesia	January 2019	18. Uganda	April 2018
9. Kazakhstan	May 2019	19. Uzbekistan	December 2017
10. Kyrgyzstan	December 2018		

Filed

1. Bolivia	June 2017	11. Paraguay	July 2017
2. Brazil	December 2017	12. Peru	July 2017
3. Colombia	September 2017	13. Rwanda	October 2017
4. Ecuador	February 2019	14. South Africa	October 2017
5. Ethiopia	January 2018	15. Tanzania	October 2017
6. Ghana	September 2017	16. Uruguay	July 2017
7. Kenya	March 2018	17. Vietnam	January 2018
8. Madagascar	March 2019	18. Zambia	September 2017
9. Myanmar	October 2018		
10. Pakistan	July 2017		

Terms and Definitions

Approved: Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

Filed: Dossier submitted and review pending.

Note

There can be no guarantee that marketing approval for Vemlidy® for the treatment of hepatitis B will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.